Phreesia Inc

Análisis de la acción Phreesia Inc (PHR)

$10.940

-0.100 (-0.91%)Al cierre

Loading chart…
Máximo
11.350
Apertura
11.170
Precio medio ponderado por volumen
11.06
Volumen
655.03K
Capitalización
1.21B
Mínimo
10.895
Importe
7.25M
EV/EBITDA, TTM
9.92

Phreesia, Inc. is a provider of comprehensive software solutions that improve the operational and financial performance of healthcare organizations. The Company's solutions include software-as-a-service (SaaS)-based integrated tools that manage patient access, registration, and payments. In addition, its solutions include clinical assessments to screen patients for a variety of physical, behavioral and mental health conditions, helping providers to understand their patients and connect them to needed services, resulting in improved health outcomes. Its Technology solutions segment provides life sciences companies, health plans and other payer organizations (payers), patient advocacy, public interest and other not-for-profit organizations with a channel for direct communication with patients. The Company's solutions also include additional products and services, such as the MediFind provider directory, which helps patients find care based on providers' specific clinical expertise.

www.phreesia.com

Análisis de IA of Phreesia Inc (PHR)

Mantener

Phreesia Inc is currently priced at $10.94, with a forward P/E ratio of 12.02, indicating potential undervaluation compared to its earnings growth prospects. However, the stock has seen a significant decline of 32.88% year-to-date and a 52.31% drop over the past year, raising concerns about its stability. The recent analyst downgrade and insider selling, which increased by 190.73%, suggest caution. Therefore, while there are some positive indicators, the risks currently outweigh the potential rewards, making it a hold rather than a buy.

Métricas de valoración

El PER previsto actual de Phreesia Inc (PHR) es 12.02, frente a su media de 5 años de 3.87.

PER previsto

Valor razonable
Media 5A P/E
3.87
P/E actual
12.02
Sobrevalorada
193.08
Infravalorada
-185.35

EV/EBITDA previsto

Valor razonable
Media 5A EV/EBITDA
-21.64
EV/EBITDA actual
9.92
Sobrevalorada
98.21
Infravalorada
-141.48

Precio/ventas previsto

Infravalorado
Media 5A P/S
3.63
P/S actual
1.28
Sobrevalorada
5.97
Infravalorada
1.29

Escenarios de precio de Alphio AI para PHR

Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.

A

Alcista

Alcista · 25%PHR

$23.17

Precio del escenario

B

Base

Base · 50%PHR

$22.64

Precio del escenario

B

Bajista

Bajista · 25%PHR

$21.67

Precio del escenario

Ballenas con PHR en cartera

P

Pale Fire Capital SE

+ Con en carteraPHR

-2.45%

Rentabilidad a 3 meses

Cronología de eventos

2026-09-02 (ET)

19:30:00

Major Indices Bounce Back as ADP Employment Data Falls Short

16:30:00

Phreesia Reports Q2 Revenue of $129.5M, Beating Expectations

2026-06-11 (ET)

14:30:00

Jeff Bezos' New AI Venture Prometheus Raises $12B, Valuation Reaches $41B

2026-05-27 (ET)

19:50:00

WTI Crude Oil Falls Below $90, Energy Sector Worst Performer

16:30:00

Phreesia Up 12% to $10.21 After Q1 Results, Affirms Guidance

Noticias

Preguntas frecuentes sobre PHR, respondidas por Alphio AI

Phreesia, Inc. is a provider of comprehensive software solutions that improve the operational and financial performance of healthcare organizations. The Company's solutions include software-as-a-service (SaaS)-based integrated tools that manage patient access, registration, and payments. In addition, its solutions include clinical assessments to screen patients for a variety of physical, behavioral and mental health conditions, helping providers to understand their patients and connect them to needed services, resulting in improved health outcomes. Its Technology solutions segment provides life sciences companies, health plans and other payer organizations (payers), patient advocacy, public interest and other not-for-profit organizations with a channel for direct communication with patients. The Company's solutions also include additional products and services, such as the MediFind provider directory, which helps patients find care based on providers' specific clinical expertise. It operates in the Technology sector (SERVICES-BUSINESS SERVICES, NEC industry).

Phreesia Inc is currently priced at $10.94, with a forward P/E ratio of 12.02, indicating potential undervaluation compared to its earnings growth prospects. However, the stock has seen a significant decline of 32.88% year-to-date and a 52.31% drop over the past year, raising concerns about its stability. The recent analyst downgrade and insider selling, which increased by 190.73%, suggest caution. Therefore, while there are some positive indicators, the risks currently outweigh the potential rewards, making it a hold rather than a buy.

Comunidad

Más ↗

Aún no hay publicaciones

Regístrate o inicia sesión para participar

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.

Empezar a operar